4BASEBIO UK SOCIETAS Cash Flow Conversion Efficiency
4BASEBIO UK SOCIETAS cash flow conversion efficiency. Based on the latest financial reports, 4BASEBIO UK SOCIETAS (4BB) has a cash flow conversion efficiency ratio of -0.703x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-7.11 Million ≈ $-865.08 USD) by net assets (GBX10.11 Million ≈ $1.23K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of 4BASEBIO UK SOCIETAS (2019–2025)
Cash flow conversion efficiency of 4BASEBIO UK SOCIETAS from 2019 to 2025. This chart illustrates how 4BASEBIO UK SOCIETAS's cash flow conversion efficiency has evolved over time, based on yearly financial data. View 4BASEBIO UK SOCIETAS share price for real-time trading data and today's change.
4BASEBIO UK SOCIETAS Cash Flow Conversion Ratio Explained
4BASEBIO UK SOCIETAS cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
4BASEBIO UK SOCIETAS Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of 4BASEBIO UK SOCIETAS ranked by their cash flow conversion efficiency. Also see how much is 4BASEBIO UK SOCIETAS worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sarawak Cable Bhd
KLSE:5170
|
0.002x |
|
Fram Skandinavien AB Series B
ST:FRAM-B
|
-2.899x |
|
Quintegra Solutions Limited
NSE:QUINTEGRA
|
0.000x |
|
Anpario Plc
LSE:ANP
|
0.112x |
|
Ridgestone Mining Inc
V:RMI
|
0.012x |
|
Rimo International Lestari Tbk PT
JK:RIMO
|
-0.030x |
|
WELLFIELD TECHNOLOG. INC.
F:K8D
|
0.028x |
|
Biora Therapeutics Inc
NASDAQ:BIOR
|
0.082x |
Annual Cash Flow Conversion Efficiency for 4BASEBIO UK SOCIETAS (2019–2025)
The table below shows the annual cash flow conversion efficiency of 4BASEBIO UK SOCIETAS from 2019 to 2025. Review 4BB FCF to total liabilities ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | GBX10.11 Million ≈ $1.23K |
GBX-14.75 Million ≈ $-1.79K |
-1.459x | -258.21% |
| 2024-12-31 | GBX26.38 Million ≈ $3.21K |
GBX-10.74 Million ≈ $-1.31K |
-0.407x | -103.24% |
| 2023-12-31 | GBX-492.00K ≈ $-59.86 |
GBX-6.18 Million ≈ $-751.68 |
12.557x | +2000.62% |
| 2022-12-31 | GBX7.12 Million ≈ $866.30 |
GBX-4.70 Million ≈ $-572.34 |
-0.661x | -181.99% |
| 2021-12-31 | GBX11.70 Million ≈ $1.42K |
GBX-2.74 Million ≈ $-333.38 |
-0.234x | -254.37% |
| 2020-12-31 | GBX15.46 Million ≈ $1.88K |
GBX-1.02 Million ≈ $-124.35 |
-0.066x | -146.45% |
| 2019-12-31 | GBX-1.89 Million ≈ $-229.96 |
GBX-269.00K ≈ $-32.73 |
0.142x | -- |
About 4BASEBIO UK SOCIETAS
4basebio PLC, together with its subsidiaries, engages in the research, development, manufacturing, and sale of synthetic DNA and RNA products in Europe, the United States, and internationally. It offers hpDNA, a double stranded linear DNA for viral and non-viral vector applications; opDNA, a partially opened, linear, double stranded DNA for in vitro transcription processes that produce mRNA for u… Read more